Performance analysis of TransCode Therapeutics (RNAZ)
Annual Return
Over the past 3 years, RNAZ has had an average annual return of -97.22%, underperforming the benchmark SPY, which returned +19.62% annual.
Over the past 5 years, RNAZ has had an average annual return of -91.71%, underperforming the benchmark SPY, which returned +12.73% annual.
Since Jul 8, 2021, RNAZ has had an average annual return of -92.06%, underperforming the benchmark SPY, which returned +13.09% annual.
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0% | -95.24% | -98.75% | -73.51% | -36.50% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +0% | +0% | +0% | ||||||||||
| 2024 | -90.48% | +0% | +0% | +0% | +200% | -50.00% | -66.67% | +0% | +100% | -50.00% | +0% | +0% | -95.24% |
| 2023 | +11.59% | -30.58% | -35.07% | -6.62% | -33.54% | -45.14% | -4.51% | -34.18% | -65.19% | -26.98% | -32.61% | -32.26% | -98.75% |
| 2022 | -9.45% | -7.39% | +35.21% | -5.21% | -32.60% | -31.52% | +12.70% | -15.49% | -8.33% | -38.91% | -40.48% | +68.20% | -73.51% |
| 2021 | -27.25% | +4.47% | -1.64% | -5.35% | -2.83% | -7.64% | -36.50% |
Drawdown analysis of TransCode Therapeutics (RNAZ)
The maximum drawdown for the RNAZ was -99.99%, occurring on Apr 22, 2024. This drawdown has not yet recovered.
The current RNAZ drawdown is -99.99%.
Since Jul 8, 2021 RNAZ has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 1 time
- 20% or more: 1 time
- 10% or more: 1 time
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.99% | Jul 12, 2021 | 699 | Apr 22, 2024 | Ongoing | Ongoing | Ongoing |